Clovis Oncology submits NDA for rucaparib to treat recurrent ovarian cancer

Clovis Oncology submits NDA for rucaparib to treat recurrent ovarian cancer

BOULDER -- Clovis Oncology (NASDAQ: CLVS) today announced it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for rucaparib as maintenance... Read More

Tuesday October 10, 2017 0 comments Tags: Boulder, Clovis Oncology, Rucaparib, Patrick J. Mahaffey, FDA

Clovis Oncology: Rucaparib improved survival in ovarian cancer patients

Clovis Oncology: Rucaparib improved survival in ovarian cancer patients

BOULDER -- ClovisOncology (NASDAQ: CLVS) today announced toplinedata from the confirmatory phase 3 ARIEL3 trial of rucaparib, which successfully achievedthe primary endpoint of improved... Read More

Monday June 19, 2017 0 comments Tags: Boulder, Clovis Oncology, Patrick Mahaffy, Rucaparib

Clovis announces FDA application for accelerated approval of cancer drug

Clovis announces FDA application for accelerated approval of cancer drug

BOULDER -- Clovis Oncology, Inc . (NASDAQ: CLVS) announced the U.S. Food and Drug Administration (FDA) has accepted Clovis New Drug Application (NDA) for accelerated approval of rucaparib and... Read More

Thursday August 25, 2016 0 comments Tags: Boulder, Clovis Oncology, Rucaparib, Patrick J. Mahaffy, Foundation Medicine

Clovis Oncology's rucaparib ovarian cancer drug granted FDA Breakthrough Therapy designation

Clovis Oncology's rucaparib ovarian cancer drug granted FDA Breakthrough Therapy designation

BOULDER Clovis Oncology Inc. (NASDAQ: CLVS) announced the U.S. Food and Drug Administration has granted Breakthrough Therapy designation for the companys investigational agent rucaparib as... Read More

By: InnovatioNews Tuesday April 7, 2015 0 comments Tags: Boulder, Clovis Oncology, Rucaparib, Patrick J. Mahaffey

Clovis Oncology begins rucaparib phase 2 clinical study with dosing of first patient at a U.S. site

Clovis Oncology begins rucaparib phase 2 clinical study with dosing of first patient at a U.S. site

BOULDER - Clovis Oncology, Inc . (NASDAQ: CLVS) today announced its Rucaparib Assessment in BRCA-mutated Pancreatic Cancer (RUCPANC) study has begun with the dosing of the first patient at a... Read More

By: InnovatioNews Monday June 16, 2014 0 comments Tags: Boulder, Clovis Oncology, Patrick J.Mahaffy, Rucaparib, RUPANC Phase 2, Susan Domchek

Clovis Oncology reports positive results for ovarian, lung cancer drugs

Clovis Oncology reports positive results for ovarian, lung cancer drugs

BOULDER - Clovis Oncology (Nasdaq: CLVS) announced initial findings from an ongoing study of its ovarian cancer-fighting drug rucaparib showed 89 percent of ovarian cancer patients treated... Read More

By: Steve Wednesday June 5, 2013 0 comments Tags: Boulder, Clovis Oncology, CO-1686, Patrick J.Mahaffy, Rucaparib

Clovis Oncology and Foundation Medicine announce diagnostic collaboration

Clovis Oncology and Foundation Medicine announce diagnostic collaboration

BOULDER - Clovis Oncology Inc. (Nasdaq: CLVS) and Foundation Medicine Inc. today announced they have entered into a collaboration aimed at developing an in-vitro diagnostic (IVD) to identify... Read More

By: Steve Monday August 6, 2012 0 comments Tags: Clovis Oncology, Foundation Medicine, Michael J. Pellini, Patrick J. Mahaffey, Rucaparib